You are here

Marburg Virus Prophylactic Medical Countermeasure

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911-QY-20-C-0099
Agency Tracking Number: C2-0545
Amount: $999,034.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: CBD18A-002
Solicitation Number: 18.A
Timeline
Solicitation Year: 2018
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-07-28
Award End Date (Contract End Date): 2022-07-28
Small Business Information
6160 Lusk Blvd., Suite C105
San Diego, CA 92121
United States
DUNS: 137551797
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Larry Zeitlin
 President
 (443) 629-0104
 larry.zeitlin@mappbio.com
Business Contact
 Larry Zeitlin
Phone: (443) 629-0104
Email: larry.zeitlin@mappbio.com
Research Institution
 Mapp Biopharmaceutical
 Kevin Whaley Kevin Whaley
 
6160 LUSK BLVD STE 105
SAN DIEGO, CA 92121
United States

 (858) 625-0335
 Nonprofit college or university
Abstract

There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operational readiness. One of the most significant limitations is that vaccines rely on the host to develop an appropriate immune response. In order to confer immunity, this endogenous immune response must be of sufficient strength and also of appropriate specificity. Further, immunity can take on the order of 1-6 months to fully develop. Monoclonal antibodies (mAbs) offer an alternative that can directly address all of these limitations associated with traditional vaccines. A controlled dose of a mAb(s) of known specificity and known protective activity can be administered to provide instantaneous immunity to the Warfighter. Through the use of wellcharacterized point mutations, the already long serum half-life of an IgG1, can be dramatically extended. The goal of this effort is to develop a mAb-based intramuscularly administered vaccine alternative for the Warfighter that would confer immediate immunity for 6-12 months against aerosolized Marburg virus.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government